3 Add System Provides Optimal Vision At All Distances, For All Levels Of Presbyopia
SYDNEY, NSW., July 19, 2021—CooperVision today introduced MyDay® multifocal contact lenses, expanding its popular premium silicone hydrogel 1-day family. Using the company’s deep expertise in optical design and prescribing practices, the new lenses are the first to feature the Binocular Progressive System, an innovative 3 add approach that caters to all levels of presbyopia with simplified fitting, optimal visual acuity at all distances and comfortable wear for exceptional performance.
“Single-vision contact lens wearers live active, on-the-go lifestyles, but as they become presbyopic, they’re typically unable to experience the same clear vision. As a result, they often turn to reading glasses over their contact lenses or drop out of the category entirely. With so many factors to consider, presbyopes need a contact lens that provides excellent vision, comfort, and health,” said Jessie Taylor, Brand Manager, CooperVision ANZ.
The CooperVision® Binocular Progressive SystemTM
The CooperVision® Binocular Progressive SystemTM debuts with MyDay® multifocal. The 3 add method uses different lens designs to optimise vision for all levels of presbyopia. These allow the eyes to work in tandem, which gives a simple initial fit and an easy progression as the near requirement increases.
Simple and Effective Fitting
CooperVison’s latest offering was created with fitting simplicity in mind. Optometrists can successfully fit 98% of patients with two pairs of MyDay® multifocal lenses or fewer when following the fitting guide.1
MyDay® multifocal fitting is incorporated into the CooperVision® OptiExpertTM app, which provides a suite of digital tools that aids clinical decision making, helps reduce chair time and increases patient success with contact lenses. This includes a new capability of refining the first fit for vision optimisation. OptiExpertTM is available to download for iOS and Android devices on the Apple App Store and Google Play. The desktop version can be used online at https://coopervision.net.au/practitioner/tools-and-calculators/optiexpert/optiexpert-web.
Clear, Optimal Vision
Under embargo until July 19, 2021, 8:00am AEST.
The innovative technology in MyDay® multifocal provides good binocularity, at both distance and near, with distance binocular visual acuity clinically similar to a wearer’s spectacle prescription.1 The lenses meet or exceed wearer vision expectations, which optometrists know is a challenge for many presbyopes. In initial studies, 86% of patients agree that MyDay multifocal met their vision needs.2
MyDay® multifocal contact lenses are designed with premium Aquaform® Technology, which provides the all-day comfort wearers need. This combines a unique balance of high oxygen permeability, a naturally wettable material, and optimum modulus for a soft and flexible lens.
Aquaform® Technology locks moisture into the lens and keeps it soft, for a comfortable lens- wearing experience. This natural wettability can help wearers’ eyes feel less dry. It also promotes a healthy lens-wearing experience by allowing high oxygen levels to flow freely through the lenses.
The attached fact sheet details the extensive power range of MyDay® multifocal.
# # #
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Jessie Taylor, Brand Manager, ANZ
Ph: +61 439 801 377 Email: email@example.com
1 CooperVision data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study at one site in the UK with MyDay® multifocal; n=104 habitual multifocal contact lens wearers.
2 CooperVision data on file, 2021. Prospective, subject-masked, randomised, bilateral, two-week dispensing study at five US sites with MyDay® daily disposable multifocal; n=58 habitual multifocal contact lens wearers.